{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Attention+Control&page=2",
    "query": {
      "intervention": "Placebo Attention Control",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Attention+Control&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T16:04:23.035Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01702181",
      "title": "A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "OPA-15406",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 92,
      "start_date": "2012-08",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-01-17",
      "last_synced_at": "2026-09-26T16:04:23.035Z",
      "location_count": 12,
      "location_summary": "Mobile, Alabama • Hot Springs, Arizona • Irvine, California + 9 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Orange Park",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01702181"
    },
    {
      "nct_id": "NCT06973577",
      "title": "P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADHD",
        "Anxiety",
        "Generalized Anxiety",
        "Social Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Centanafadine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 315,
      "start_date": "2025-03-26",
      "completion_date": "2026-04-29",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-09-26T16:04:23.035Z",
      "location_count": 46,
      "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 41 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06973577"
    },
    {
      "nct_id": "NCT00323947",
      "title": "Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Disorder With Hyperactivity",
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Extended Release Methylphenidate (OROS-Methylphenidate)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Years to 18 Years"
      },
      "enrollment_count": 33,
      "start_date": "2003-05",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2013-08-01",
      "last_synced_at": "2026-09-26T16:04:23.035Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323947"
    },
    {
      "nct_id": "NCT02401282",
      "title": "Attention and Social Behavior in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anxiety"
      ],
      "interventions": [
        {
          "name": "Attention Bias Modification",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Dot-probe task",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Penn State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "9 Years to 12 Years"
      },
      "enrollment_count": 251,
      "start_date": "2011-12",
      "completion_date": "2016-12-17",
      "has_results": false,
      "last_update_posted_date": "2018-01-16",
      "last_synced_at": "2026-09-26T16:04:23.035Z",
      "location_count": 1,
      "location_summary": "University Park, Pennsylvania",
      "locations": [
        {
          "city": "University Park",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02401282"
    },
    {
      "nct_id": "NCT05538208",
      "title": "The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "8 Years to 20 Years"
      },
      "enrollment_count": 105,
      "start_date": "2024-06-07",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-09-26T16:04:23.035Z",
      "location_count": 19,
      "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 14 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05538208"
    },
    {
      "nct_id": "NCT06441643",
      "title": "Next Generation Rocklatan",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "AR-17043 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "PG043 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil 0.02% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "AR-17043 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 426,
      "start_date": "2024-09-04",
      "completion_date": "2025-11-14",
      "has_results": false,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-09-26T16:04:23.035Z",
      "location_count": 12,
      "location_summary": "Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06441643"
    },
    {
      "nct_id": "NCT05112562",
      "title": "Attentional Bias Modification Training for E-cigarette Users",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "E-cigarette Use",
        "Tobacco Use Cessation"
      ],
      "interventions": [
        {
          "name": "Computerized attentional bias modification training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo attention control training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Wisconsin, Milwaukee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "18 Years to 29 Years"
      },
      "enrollment_count": 50,
      "start_date": "2021-06-09",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-11-04",
      "last_synced_at": "2026-09-26T16:04:23.035Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05112562"
    },
    {
      "nct_id": "NCT07547761",
      "title": "A Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Body Odor"
      ],
      "interventions": [
        {
          "name": "NOBO Aqueous Deodorant",
          "type": "OTHER"
        },
        {
          "name": "Placebo Aqueous Deodorant",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Kingdom",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 5,
      "start_date": "2026-04-16",
      "completion_date": "2026-05-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-09-26T16:04:23.035Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07547761"
    },
    {
      "nct_id": "NCT00922636",
      "title": "A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "LY2216684",
          "type": "DRUG"
        },
        {
          "name": "Methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Placebo (tablet)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (capsule)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 340,
      "start_date": "2009-06",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2014-08-18",
      "last_synced_at": "2026-09-26T16:04:23.035Z",
      "location_count": 17,
      "location_summary": "Spring Valley, California • Bradenton, Florida • Gainesville, Florida + 14 more",
      "locations": [
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00922636"
    },
    {
      "nct_id": "NCT01519271",
      "title": "Mild Cognitive Impairment in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Exelon Patch (rivastigmine transdermal system)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Patches",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 28,
      "start_date": "2011-12",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2017-04-07",
      "last_synced_at": "2026-09-26T16:04:23.035Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01519271"
    }
  ]
}